| Rx0000356 |
Radius Health, Inc. |
03/31/2021 |
70539000101 |
TYMLOS 80 MCG Pen |
01/01/2021 |
155.34 |
2121.72 |
04/28/2031 |
Single Source Drug |
None |
1 |
Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients.
Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to:
- The clinical and health outcomes value of our products to patients and payors.
- Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them.
- Responsible and competitive prices, in line with current treatment costs where other treatment options exist.
- Corporate business strategy, including costs and profitability.
- Consideration of other factors such as Annual CPI-U rates.
- R&D investment priorities and budgets to identify future medicines to improve the lives of patients
- Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/29/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
| Rx0000356 |
Radius Health, Inc. |
03/31/2021 |
70539000102 |
TYMLOS 80 MCG Pen / Carton |
01/01/2021 |
155.34 |
2121.72 |
04/28/2031 |
Single Source Drug |
None |
1 |
Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients.
Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to:
- The clinical and health outcomes value of our products to patients and payors.
- Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them.
- Responsible and competitive prices, in line with current treatment costs where other treatment options exist.
- Corporate business strategy, including costs and profitability.
- Consideration of other factors such as Annual CPI-U rates.
- R&D investment priorities and budgets to identify future medicines to improve the lives of patients
- Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/29/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292020111 |
Chemet 100mg, 100 capsules, 1 bottle |
01/06/2021 |
152.67 |
2061.06 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
Manufacturing changes contributed to increasing the WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292081155 |
Cosmegen Inj 0.5mg, 1 vial |
01/06/2021 |
204.43 |
2248.68 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292010401 |
Desoxyn 5mg, 100 tabs, 1 bottle |
01/06/2021 |
170.17 |
1871.89 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
52292012252 |
NeoProfen Inj 2ml vial, 3 vials |
01/06/2021 |
243.87 |
2682.52 |
03/02/2032 |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292030401 |
Tranxene 7.5 mg, 100 tabs, 1 bottle |
01/06/2021 |
118.60 |
1304.58 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000166 |
Redhill Biopharma, Inc. |
03/31/2021 |
71068000110 |
AEMCOLO (rifamycin sodium) 12 194mg Oral Tablets |
01/01/2021 |
5.13 |
176.37 |
05/03/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/18/2019 |
Cosmo Technologies |
None |
1 |
Please see Supporting Docs for full Press Release details.
RedHill did not purchase the product from Cosmo, but instead Cosmo purchased 1,714,286 ADS at an agreed value of $12 million as an upfront payment, plus the ADS as part of the 36.3 million investment into RedHill. |
157.00 |
144.00 |
2018 |
144.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=470 |
None |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
06/30/2021 |
71332000101 |
Tavalisse 100 mg oral tablet 60 count |
06/29/2021 |
590.00 |
12400.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
06/30/2021 |
71332000201 |
Tavalisse 150 mg oral tablet 60 count |
06/29/2021 |
590.00 |
12400.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |